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ABSTRACT 1 
Previous studies reported high sensitivity and specificity of the Swiss Narcolepsy Scale (SNS) for the 2 
diagnosis of narcolepsy type 1. We used data from the Bern Sleep-Wake Database to investigate the 3 
discriminating capacity of both the SNS and the Epworth Sleepiness Scale (ESS) to identify narcolepsy 4 
type 1 and type 2 in patients with central disorders of hypersomnolence (CDH) or sleepy patients with 5 
obstructive sleep apnea (OSA). In addition, we aimed to develop a simplified version of the SNS. 6 
We created the two-item short-form SNS (sSNS), based on the discriminative capability of the models 7 
including all possible combinations of the five questions of the SNS. 8 
Using the previously published co-efficiencies, we confirmed the high capacity of the SNS in 9 
identifying narcolepsy type 1. The updated SNS (based on new co-efficiencies and cut-off) and the 10 
sSNS showed high capacity and were both superior to ESS in identifying narcolepsy type 1. The sSNS 11 
correlated significantly with the SNS (r = -0.897, p < 0.001). No scale showed sufficient discrimination 12 
for narcolepsy type 2. 13 
This is the largest cohort study that confirms the discriminating power of SNS for narcolepsy type 1 in 14 
patients with hypersomnolence and the first study to assess its discriminative power for narcolepsy 15 
type 2. The easy-to-use and easy-to-calculate short-form scale has a high discriminating power for 16 
narcolepsy type 1 and may be used as screening tool, especially among general practitioners, to identify 17 
patients and accelerate their referral to a center of expertise. 18 
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INTRODUCTION 1 
Narcolepsy belongs to the group of central disorder of hypersomnolence (CDH) and is clinically 2 
characterized by excessive daytime sleepiness (EDS), cataplexy (in narcolepsy type I, NT1), 3 
hypnagogic or hypnopompic hallucinations, sleep paralysis and sleep fragmentation[1]. 4 
Narcolepsy has an estimated prevalence of 0.05% and symptom onset typically peaks during the second 5 
decade of life[2,3].  6 
There is evidence for a delayed referral of patients with narcolepsy to a specialized center[4] and 7 
delayed diagnosis of narcolepsy[5,6] often due to lack of recognition of signs and symptoms and lack 8 
of knowledge about CDH in a broad medical community[4]. 9 
The correct diagnosis of narcolepsy is based on clinical features and objective measures including 10 
multiple sleep latency test (MSLT), polysomnography, and/or measurement of decreased or absent 11 
hypocretin in cerebrospinal fluid supported by HLA DQB1*0602 testing. Questionnaires such as the 12 
Ullanlinna Narcolepsy Scale (UNS)[7], Narcolepsy Severity Scale[8] and the Epworth Sleepiness 13 
Scale (ESS)[9,10] are frequently used in screening of EDS as well as evaluation of treatment effects in 14 
narcolepsy, but have a limited discriminative capability especially among patients with 15 
hypersomnolence[9-12]. ESS allows calculating a score that quantifies daytime sleepiness, respectively 16 
how likely participants fall asleep in different passive situations. It consists of 8 items with a 4-step 17 
rating scale. Total score ranges from 0 to 24. Excessive daytime sleepiness is defined by an ESS value 18 
≥10[13,14].  19 
In 2004, we introduced a new scale, the Swiss Narcolepsy Scale (SNS)[12] aiming to develop a simple, 20 
short and specific screening questionnaire for identifying patients with narcolepsy. The SNS is a self-21 
administered narcolepsy screening instrument which contains five questions and assesses the following 22 
parameters: (1) the inability to fall asleep; (2) feeling unrefreshed in the morning; (3) taking a nap at 23 
noon; (4) weak knees/buckling of the knees during emotions such as laughing, happiness, or anger and 24 
(5) sagging of the jaw during emotions such as laughing, happiness, or anger. A calculated value (with 25 
defined multipliers) of <0 is indicating the presence of narcolepsy[12].  26 
This initial study compared the SNS with the UNS in 57 patients with NT1, 56 with non-narcoleptic 27 
hypersomnolence, and 40 healthy controls, and reported high sensitivity (96%) and specificity (98%) 28 
for NT1 compared to a similar sensitivity (98%) but lower specificity (56%) of the UNS[12]. This 29 
initial study and a recent validation study[15] focused mainly on the diagnostic accuracy of SNS in 30 
detecting NT1 against other types of hypersomnolence. Studies comparing the discriminating power 31 
of SNS and ESS for NT2 among patients with hypersomnolence are lacking.   32 
 33 
In the current study, we aim 1) to assess the capacity of the SNS and the ESS in discriminating NT1 34 
and NT2 in a larger cohort of new patients with disorders of hypersomnolence, 2) to provide an update 35 
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version of the SNS based on new scoring coefficients and optimal cut-off point and 3) to develop a 1 
simplified short-form of the SNS to increase practicability in a daily practice of a broad community of 2 
physicians. In an effort to increase applicability of the SNS and mainly of the sSNS in a general 3 
practitioner's usual practice, we additionally assessed the discriminative power of the scales in an 4 
expanded cohort that included also patients suffering from obstructive sleep apnea, one of the most 5 
common causes of excessive sleepiness among patients who visit a general practitioner. 6 
 7 
METHODS AND PATIENTS 8 
This is a retrospective cohort study based on data from the Bern Sleep-Wake Database (Dietmann et 9 
al submitted). The protocol for the establishment of the database for clinical and research purposes was 10 
approved by the local ethics committee (Kantonale Ethikkommission Bern, 2016-00409). For this 11 
study, data sets collected between 2001 and 2016 for clinical purposes were used. Patients have been 12 
admitted to the Sleep-Wake-Epilepsy Center, Department of Neurology, Inselspital, University 13 
Hospital Bern, Bern, Switzerland for evaluation of suspected disorder of hypersomnolence. Patients 14 
underwent clinical routine work-up including clinical consultations and electrophysiological 15 
examinations (polysomnography, multiple sleep latency test, maintenance of wakefulness test, 16 
psychovigilance test and actigraphy), all patients filled in a set of questionnaires related to sleep-wake-17 
disorders. Final diagnosis was reviewed for this study by two independent sleep specialists (A.D. and 18 
M.G.C.) according to the International Classification of Sleep Disorders (ICSD-3)[16] using medical 19 
history from hospital records, laboratory data, electrophysiological work-up of subjective complaints 20 
(including PSG, MSLT, MWT and actigraphy) and a battery of sleep-wake questionnaires. Patients 21 
included in this study were diagnosed with narcolepsy (type 1 and 2) or other disorder of 22 
hypersomnolence, including idiopathic hypersomnia, hypersomnolence due to a medical disorder, 23 
hypersomnolence associated with a psychiatric disorder, insufficient sleep syndrome, long sleepers, 24 
EDS of unknown origin and sleepy (ESS>10) patients who have completed the SNS scale and were 25 
diagnosed with obstructive sleep apnea (Apnea-Hypopnea Index, AHI>5/h). 26 
 27 
Clinical Assessment 28 
The assessment of the clinical and epidemiological sleep-wake profile of the patients was based on the 29 
“Bern Sleep Questionnaire”. The questionnaire contains 110 questions about demographics, reasons 30 
for referral to sleep laboratory, general information about sleep-wake habits and sleep problems, 31 
breathing and circulation, parasomnias and potential trigger factors, dreaming, waking-up, tiredness 32 
and sleepiness, cataplexy, hallucinations, stress, well-being, drugs, medication, neurological, 33 
psychiatric and other comorbidities, as well as information on family history. Furthermore, all 34 
questions included in the ESS, SNS and UNS are included in the Bern Sleep Questionnaire.  35 
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 1 
Statistical model 2 
To assess the diagnostic accuracy of the SNS, sensitivity and specificity were calculated for the cut-3 
off value of 0. Additionally, logistic regression was used to model the effect of the SNS on the 4 
probability of NT1 and NT2 separately. Model coefficients of the individual questions in the SNS were 5 
also re-assessed using logistic regression. The Hosmer-Lemeshow goodness-of-fit test and the Brier 6 
score were subsequently calculated to test for calibration and agreement between diagnosis and 7 
prediction, respectively. Complete cases analyses were performed. 8 
To derive the new short-form SNS (sSNS), logistic regression and AUC for all combinations of 9 
questions was used to rank the discriminative ability of the combinations of questions. Although 10 
models with four and five questions typically showed higher discriminative abilities, a two question 11 
model (including at least one question on cataplexy and one question on awakening) was desirable. 12 
The best two-question model was chosen for further analyses. The cut-off for predicting narcolepsy 13 
was selected by summing the sensitivity and specificity for each possible predicted value from the 14 
model and selecting the cut-off with the largest sum. Cut-offs reported are on the linear predictor scale. 15 
Validation of the sSNS for NT1 and the re-parameterized SNS to predict NT1 was assessed via internal 16 
bootstrap validation to estimate the optimism in the AUC, Brier score and calibration plot slope and 17 
intercept. Briefly, a training sample was drawn and the model was refit in that sample, with Briers 18 
score and a test of calibration plot intercept and slope calculated for the training sample. The statistics 19 
from that training model were then compared to the original sample for an estimate of the test 20 
performance. Optimism was then calculated based on the difference between training and test 21 
performance. This procedure was performed 2000 times and the average optimism subtracted from the 22 
statistics from the original model to derive a corrected performance.  23 
As an exploratory analysis, the best cut-off for ESS to determine NT1 and NT2 was assessed by 24 
calculating sensitivity and specificity at each possible cut-off (each value between the minimum and 25 
maximum), summing the sensitivity and specificity and determining the cut-off with the highest sum. 26 
AUC was also calculated. 27 
Analyses were performed in Stata 15.1 and R 3.4.2  28 
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RESULTS 1 
Patients 2 
In our data set, we identified 299 individuals with a disorder of hypersomnolence who have completed 3 
the SNS scale. The final cohort consisted of patients with NT1 (30%), NT2 (7%), idiopathic 4 
hypersomnia (15%), hypersomnolence due to a medical condition or a substance (5%), 5 
hypersomnolence associated with a psychiatric disorder (26%) and hypersomnolence of unknown 6 
origin (17%). Mean age was 33 years (range 23-48) and the male/female ratio was 1.45. For NT1 and 7 
NT2 mean age was 31 (range 23-42) and 25 years (range 19-34), and the male/female ratio was 2.0 8 
and 2.2 respectively. Table 1 presents the demographic and clinical characteristics of the patients with 9 
CDH. 10 
Expanding the cohort of patients who completed the SNS and including not only patients with CDH 11 
but also sleepy (ESS>10) patients with obstructive sleep apnea (AHI >5/h) we could identify 473 12 
individuals.  13 
 14 
The discriminating power of the SNS for NT1 and NT2  15 
In our cohort, the SNS showed a sensitivity of 86% and a specificity of 88% in detecting NT1 against 16 
other types of hypersomnolence using the previously published scoring coefficients and the published 17 
cut-off of zero[12]. A Brier score of 0.87 indicated relatively poor agreement between observed and 18 
predicted outcome (NT1), although the Hosmer-Lemeshow test (p=0.70) was not statistically 19 
significant suggesting a normal calibration (Table 2). For the detection of NT2 against other types of 20 
hypersomnolence the SNS showed a sensitivity of 25% and a specificity of 71% (Table 2). The 21 
distribution of the SNS values in patients with NT1 are shown in Figure 1. 22 
 23 
The discriminating power of the updated SNS for NT1 and NT2  24 
Based on this new cohort, we recalculated the published model coefficients for scoring SNS and 25 
determined a new cut-off point of -1.83. The parameterization of the model to predict NT1 (rather than 26 
not-NT1, as in the original parameterization) resulted in the following formula: 27 
𝑄1 × (−0.47) + 𝑄2 × (−0.83) + 𝑄3 × 0.58 + 𝑄4 × 0.56 + 𝑄5 × 1.45 − 2.75 ≥ −1.83 28 
The sensitivity of the updated SNS for detecting NT1 against other types of hypersomnolence was 91% 29 
and the specificity 82%. Brier score was 0.07, indicating good agreement between observed and 30 
predicted outcomes (NT1). The Hosmer-Lemeshow test was also non-significant (p=0.39) suggesting 31 
a normal calibration (Table 2).  32 
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The updated SNS showed a sensitivity of 63% and a specificity of 70% in detecting NT2 against other 1 
types of hypersomnolence, using the revised scoring coefficients and the revised cut-off of -2.75 (Table 2 
2). 3 
 4 
The discriminating power of the simplified form SNS (sSNS) for NT1 and NT2  5 
The 2-item simplified form from the SNS (sSNS) was created based on the discriminative capability 6 
of the models including all possible combinations of the five SNS questions. Among them, the 7 
combination of SNS question 2 (feeling of being unrefreshed in the morning) and question 5 (reports 8 
of episodes with muscle weakness in the face/neck related to emotions) showed the highest 9 
discriminative capability for NT1 (supplementary table 1 and supplementary table 2). The accuracy for 10 
the sSNS in detecting NT1 was comparable to that of the SNS reaching 80% sensitivity and 92% 11 
specificity (Table 2). Brier score was 0.08, indicating good agreement, and the Hosmer-Lemeshow test 12 
was non-significant (p= 0.26), suggesting a good calibration. The sSNS score correlate significantly 13 
with the updated SNS (r = -0.89, p <0.001).  14 
Based on the sensitivity and specificity of the models to predict NT1 we determined a cut-off point of 15 
-0.68 for the sSNS. The parameterization of the model to predict NT1 resulted in the following formula: 16 
Q2 × −0.82 +  Q5 × 1.70 –  0.74 ≥  −0.68 17 
The distribution of the sSNS values in patients with NT1 are shown in Figure 2. Model parameters are 18 
presented in Table 2.  19 
We used the above formula to create an easy-to-use grid, based on the possible answers in sSNS (Q2 20 
and Q5 of the SNS), in order to assess probability of NT1 diagnosis against other disorders of 21 
hypersomnolence (Figure 3).  22 
None of the combinations among SNS questions showed sufficient capacity in discriminating NT2 23 
within the cohort of patients with hypersomnolence (data not shown).  24 
 25 
The discriminating power of the original SNS, the updated SNS and the sSNS for NT1 among 26 
patients with CDH or OSA  27 
We then assessed the discriminating capability of SNS, updated SNS and sSNS to discriminate NT1 28 
among patients with CDH or sleepy patients with obstructive sleep apnea (OSA).  29 
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The original SNS, using the previously published scoring coefficients and the published cut-off of 1 
zero[12], showed a sensitivity of 83.3% (95% CI 73.1 – 90.2%) and a specificity of 90.6% (95%CI 2 
86.9 – 93.2%) in detecting NT1 among patients with CDH or OSA.  3 
The sensitivity of the reparametrized SNS for detecting NT1 among patients with CDH or OSA was 4 
93% (95%CI 84.8 – 97.0%) and the specificity 82.3% (95%CI 77.9 – 86.0%).  5 
The sensitivity of the sSNS for detecting NT1 among patients with CDH or OSA was 83% (95%CI 6 
72.9 – 89.7%), and the specificity 82.6% (95%CI 78.6 – 86.0%). 7 
 8 
The discriminating power of the ESS for NT1 and NT2  9 
In our cohort, the sensitivity of ESS score, using the typical cut-off of sleepiness (ESS ≥10) was 68% 10 
and specificity was 56% for the identification of NT1 against other disorders of hypersomnolence 11 
(Table 3). By using various ESS cut-off’s, finally applying the one (ESS ≥18) with the best AUC, the 12 
sensitivity (51%) and specificity (78%) for identifying NT1 remained low. 13 
Similarly, by using various ESS cut-off’s, applying the one (ESS ≥10) with the best AUC, the 14 
sensitivity for identifying NT2 against other disorders of hypersomnolence was 93% but specificity 15 
was very low (17%). 16 
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DISCUSSION 1 
This is the largest known retrospective cohort study to assess the discriminative capacity of the SNS 2 
for narcolepsy. Our data confirmed the previously reported high capacity of the SNS in identifying 3 
NT1 against other types of hypersomnolence[12]. In addition, we updated the SNS by recalculating the 4 
model coefficients for scoring SNS and defining new cut-off scores for the scale. The capacity of the 5 
updated SNS for discriminating NT1 against other disorders of hypersomnolence was comparable to 6 
the capacity of the original SNS.  7 
There is ample evidence for a delayed diagnosis of narcolepsy often due to the absence or lack of 8 
recognition of common narcolepsy symptoms, especially cataplexy. Therefore, the implementation of 9 
simple, easy-to-use, and reliable questionnaires on the symptom-based suspicion of narcolepsy and its 10 
subtypes in primary care may significantly increase the referral accuracy and improve resource 11 
utilization by narrowing the differential diagnosis upon referral. In an effort to increase its 12 
practicability, we aimed to simplify the SNS and introduced a simplified form (sSNS) which contains 13 
only two questions.  14 
The sSNS correlated with the full SNS and demonstrated comparable validity with the SNS in detecting 15 
NT1 against other types of hypersomnolence. We created an easy-to-use grid, based on the sSNS 16 
formula, to simplify further the prediction of NT1, by selecting the relevant cell. 17 
We then applied the original SNS, the updated SNS and the sSNS in a larger cohort of patients 18 
including sleepy patients with obstructive sleep apnea (OSA). The discriminative power of all scales, 19 
including the two-questions sSNS, remained satisfactory. This increases the applicability of the SNS 20 
and mainly of the sSNS in a general practitioner's usual practice, as OSA is one of the most common 21 
causes of pathological level of sleepiness among patients who visit a general practitioner.  22 
Our data from the sSNS suggest that the combined reports of episodes with muscle weakness in the 23 
face/neck related to emotions and the subjective feeling of restorative night time sleep can better predict 24 
the NT1 among patients with hypersomnolence. Indeed, the cataplectic attacks and the restorative 25 
nature of sleep are considered, among sleep specialists, typical symptoms for NT (and specifically for 26 
NT1), in contrast to the absence of cataplexy in NT2 or to the non-restorative nature of sleep in other 27 
CDH such as idiopathic hypersomnia. However, often these two important sleepiness features are not 28 
implemented in the standard first-line screening of a sleepy patient. 29 
Furthermore, we compared the capability of the SNS, the sSNS and the ESS to discriminate NT1 30 
against other disorders of hypersomnolence. Our data further support the superiority of SNS and sSNS 31 
against ESS in identifying NT1, even if these higher cut-off ESS scores were used.  32 
Finally, this is the first study to report the poor discriminative capacity of SNS for NT2. Both SNS and 33 
the updated SNS, showed low capacity in identifying NT2 against other disorders of hypersomnolence. 34 
No combination of the five SNS questions showed a satisfactory discriminative ability. Similarly, ESS 35 
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showed low validity in identifying NT2 against other disorders of hypersomnolence even if the higher 1 
cut-off ESS scores were used. These findings are consistent with previous data showing that the 2 
distinction between narcolepsy without cataplexy (NT2) and other disorders of hypersomnolence 3 
(mainly the idiopathic hypersomnia) remains ambiguous, not seldom due to a diagnosis change over 4 
the time[17]. 5 
The retrospective approach and the small N number of patients with NT2 consist two important 6 
limitations of our study. Due of the retrospective design of the study, not all patients with CDH have 7 
completed the SNS, and therefore had to be excluded from the analysis. In addition, the small sample 8 
size of NT2 patients may have limited our ability to detect the discriminative power of the scales for 9 
NT2 in this cohort. Prospective cohort studies would overcome these limitations. 10 
 11 
CONCLUSIONS 12 
The SNS is a useful and valid complementary tool for the diagnosis of NT1 against other types of 13 
hypersomnolence. In this study, we introduce its short form (sSNS), a two-questions, simple, easy-to-14 
use, easier-to-calculate and reliable questionnaire in particular to be used in primary care as a screening 15 
tool for narcolepsy in patients with hypersomnolence. This could decrease the delay and increase the 16 
accuracy of referral of patients with hypersomnolence to a specialized sleep center for narcolepsy 17 
specific diagnostic. Finally, our data suggest that SNS and ESS are not the ideal tools for the 18 
discrimination of NT2 against other disorders of hypersomnolence.  19 
Although further confirmatory studies and most importantly prospective studies on clinical biomarkers 20 
for disorders of hypersomnolence are needed, our data could be used for the improvement of diagnostic 21 
processes in these conditions and the development of more specific screening scales in the future. 22 
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FIGURES CAPTIONS  1 
 2 
Figure 1. Distribution of the SNS for NT1. Black points indicate correct predictions, grey points 3 
indicate incorrect (false negative) predictions. Sensitivity and specificity values are shown. 4 
NT1, narcolepsy type 1; SNS, swiss narcolepsy scale 5 
 6 
Figure 2 Distribution of the sSNS score for NT1 patients. Black points indicate correct predictions, 7 
grey points indicate incorrect (false negative) predictions. Sensitivity and specificity values are shown. 8 
NT1, narcolepsy type 1; sSNS, short-form swiss narcolepsy scale 9 
  10 
Figure 3 Grid to predict NT1. Black regions suggest the possibility of NT1. Values in the cell represent 11 
probability of NT1 against other types of hypersomnolence. 12 
P: probability; NT1, narcolepsy type 1 13 
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Demographic and clinical characteristics n (%) or median (lq, uq) 
Age  32.9 (22.8, 47.7) 
Gender  
    male 177 (59%) 
    female 122 (41%) 
ESS mean score (±SD) 11.6 (±6.8) 
  
Disorders of hypersomnolence 299 (100%) 
NT1 69 
NT2 16 
Idiopathic hypersomnia 35 
Hypersomnia due to a medical disorder 12 
Hypersomnia due to a medication or substance 2 
Hypersomnia associated with a psychiatric disorder 59 
Insufficient sleep syndrome 91 
Long sleeper 10 
EDS unclear etiology 35 
Table 1 Demographic and clinical characteristics of the cohort 
LQ, lower quartile; UQ, upper quartiles; SNS, swiss narcolepsy scale; NT1, narcolepsy type 
1; NT2, narcolepsy type 2, EDS: excessive daytime sleepiness 
 
Table 1
 
SNS* Updated SNS** sSNS 
NT1 NT2 NT1 NT2 NT1 NT2 
Cut-off 0 0 -1.83 -2.75 -0.68 -2.26 
Sensitivity (95% CI ) 
0.86 
(0.75 - 0.92) 
0.25 
(0.10 - 0.49) 
0.93 
(0.84 - 0.97) 
0.63 
(0.39 - 0.82) 
0.80 
(0.69 - 0.88) 
0.44 
(0.23 - 0.67) 
Specificity (95% CI ) 
0.88 
(0.83 - 0.91) 
0.71 
(0.65 - 0.76) 
0.82 
(0.76 - 0.86) 
0.70 
(0.64 - 0.75) 
0.92 
(0.87 - 0.95) 
0.83 
(0.78 - 0.87) 
Hosmer-Lemeshow 
goodness-of-fit 
0.70 0.02 0.39 0.28 0.26 0.00 
Brier score 0.87 0.87 0.07 0.05 0.08 0.22 
AUC 0.95 0.54 0.96 0.68 0.92 0.82 
Table 2 Sensitivities and Specificities of SNS and its short-form (sSNS) in discriminating 
NT1 and NT2 in a cohort of individuals with hypersomnolence  
NT1, narcolepsy type I; NT2, narcolepsy type II; CI, confidence interval; AUC, area under the estimated curve; SNS, swiss 
narcolepsy scale; sSNS, Short form SNS. 
*SNS in the current cohort based on the previously published scoring coefficients(Sturzenegger and Bassetti, 2004) 
**SNS in the current cohort based on the updated scoring coefficients. 
 
Table 2
 ESS 
NT1 NT2 
Sensitivity (95% CI ) 
0.56 
(0.46 – 0.65) 
0.96 
(0.82 – 0.99) 
Specificity (95% CI ) 
0.68 
(0.61 – 0.75) 
0.07 
(0.05 – 0.11) 
Hosmer-Lemeshow                           
goodness-of-fit 
0.288 0.225 
Brier score 0.210 0.093 
AUC 0.681 0.501 
Table 3 Sensitivities and Specificities of ESS in discriminating NT1 and NT2 in the cohort of 
patients with hypersomnolence. 
 
ESS Epworth Sleepiness Scale; NT1, narcolepsy type I; NT2, narcolepsy type II; CI, confidence interval; AUC, 
area under the curve 
 
 
Table 3
